<DOC>
	<DOC>NCT02769273</DOC>
	<brief_summary>Prospective, international, multi-center, single arm, observational study to continue to assess the treatment by the Stellarex™ OTW Drug-coated Angioplasty Balloon in superficial femoral and/or popliteal arteries according to the Instructions for Use in a broad, real-world, claudicant or ischemic rest pain patients population per the institution's standard practice.</brief_summary>
	<brief_title>Stellarex Vascular E-Registry</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patients intended to be treated with Stellarex for denovo or restenotic lesions of the femoropopliteal arteries Rutherford Clinical Category (RCC) 23 or 4 indicated for a Percutaneous Transluminal Angioplasty according to local applicable guidelines Age ≥18 years old Life expectancy &gt; 1 year Is able and willing to provide written informed consent prior to enrollment in the study (as applicable) Is able and willing to come on site or to be contacted by phone for the followup Patients with any medical condition that would make him/her inappropriate for treatment with Stellarex as per Instructions for Use (IFU) or investigator's opinion Patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints Patients that in the judgment of the investigator would need treatment below the knee before and/or during the index procedure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>